The Moses H. Cone Memorial Hospital, also known as Moses Cone Hospital, is a 517-bed tertiary care facility located in Greensboro, North Carolina. The hospital opened in 1953 on North Elm Street as a 310-bed community hospital. Moses Cone Hospital is the central facility of Cone Health, a network of medical care facilities serving Guilford County, North Carolina and surrounding areas. As of 2019, its president is Preston Hammock.Moses Cone Hospital is the largest hospital in its four county region (Alamance, Guilford, Randolph, and Rockingham counties). The hospital is a designated Level II Trauma Center..
We conducted a cross-sectional study to identify the frequency of optimized oral antibiotic regimens at transitions of care (TOC) in patients diagnosed with respiratory, urinary tract, or skin structure infections. An optimal regimen was identified in 62.5% of patients at TOC, highlighting opportunities for antimicrobial stewardship interventions at TOC.
Background While guidelines suggest intravenous (IV) iron to improve functional status and quality of life (QoL) in patients with NYHA class II-III heart failure (HF), continuous flow left ventricular assist device (CF-LVAD) recipients were not included in early IV iron studies. Our study compared outcomes between patients who did and did not receive IV iron during the index admission following Abbott HeartMate III (TM) (HM 3) CF-LVAD placement. Methods Thirty-three adult patients with a HM3 placed at our institution who received early post-operative IV iron (n = 20) or no IV iron replacement (n = 13) were compared. The co-primary outcomes were mean change in quality of life (by the Minnesota Living with Heart Failure Questionnaire [MLHFQ]) and 6-minute walk distance (6MWD) from baseline to first >90 day clinic follow-up. Results At first clinic follow-up there was no significant difference between the IV iron and no-IV iron groups in MLHFQ (-27 +/- 38 vs -21 +/- 41, P = .8822) or 6MWD (360 +/- 740 vs 786 +/- 722, P = .208). Conclusion Patients receiving IV iron during index admission following HM3 implantation did not experience an improvement in quality of life or functional capacity when compared to those who did not receive IV iron.
BACKGROUNDDirect mechanical ventricular actuation (DMVA) using the Anstadt Cup is effective for non-blood contacting biventricular support. Pneumatic regulation of a silicone device augments ventricular pump function. Vacuum attachment facilitates diastolic augmentation critical for biventricular support. This report reviews outcomes in patients supported for bridge to transplant.METHODSDMVA was approved by the Institutional Review Board at Duke University for refractory cardiogenic shock in potential candidates for cardiac transplantation. Devices with silicone membranes were controlled using pneumatic drive systems. Explanted hearts underwent extensive histologic examination.RESULTSFive patients met inclusion criteria. All exhibited immediate return of physiologic pulsatile flow and reduced pulmonary pressures during device insertion. Vasopressors, inotropes, and balloon pump support were discontinued at implant or within 48 hours. Installation via left thoracotomy (n=4) took under 5 minutes. Post-cardiotomy support (n=1) enabled routine decannulation. Support ranged from 2 to 84 days. Long term survivors (n=2) received 2 days DMVA bridging to cardiac transplantation and 7.5 days DMVA for acute myocarditis. There were no device related complications. An expert cardiovascular pathologist found no evidence of device related myocardial trauma or injury (n=4) and no adverse affects on bypass grafts (n=1). Recovery was deemed futile (n=3) following diffuse cerebral emboli from prior aortic cross clamp and extended CPR, and for pre-existing sepsis leading to end-organ failure.CONCLUSIONSDMVA using the Anstadt cup effectively supported the failing or arrested heart in humans without adverse cardiac effects. Unique diastolic augmentation, return of physiologic pulsatile flow and no blood contact contribute to device efficacy.